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Abstract. Heparin blocks the phorbol ester-induced
progression of nontransformed cells through the Go/G,
phase (Wright, T.C., L. A. Pukac, J. J. Castellot,
M. J. Karnovsky, R. A. Levine, H .-Y. Kim-Park, and
J. Campisi. 1989. Proc. Natl. Acad. Sci. USA. 86:
3199-3203) or G, to S phase (Reilly, C. F., M . S.
Kindy, K. E. Brown, R. D. Rosenberg, and G. E.
Sonenshein. 1989. J. Biol. Chem. 264:6990-6995) of
the cell cycle. Cell cycle arrest was associated with
decreased levels of stage-specific mRNAs suggesting
transcriptional regulation of cell growth. In the present
report, we show that heparin selectively repressed
TPAinducible AP-1-mediated gene expression. Hepa-
S
EVERAL laboratories have recently demonstrated that
cell matrix glycosaminoglycans (GAGs)' and heparin
potently suppress entry of cells into S-phase in response
to mitogens by arresting them early in the cell cycle (Reilly
et al., 1986; Benitz et al ., 1986; Wright et al ., 1989; Reilly
et al., 1989 ; Jackson et al., 1991). Inhibition of cell growth
was not due to the sequestration of serum nutrients, mito-
gens, and growth factors (Reilly et al., 1986; Benitz et al.,
1986) but rather involved the high affinity binding of heparin
(Kd -10- 9) to specific cell surface receptors (Castellot et
al ., 1985; Resink et al., 1989) and internalization of the
GAGs characterized by a ti/2 of 15-20 min in primary cell
cultures. Inhibition of cell migration and proliferation in
vivo after heparin perfusion has also been reported (Clowes
and Karnovsky, 1977; Guyton et al., 1980) . Subsequent stud-
ies by Fedarko and Conrad (1986) and Ishihara et al. (1986)
demonstrated that the cellular uptake of specific GAG sub-
fractions by hepatocytes resulted in their nuclear seques-
tration and in cell cycle arrest. Heparin has been reported
to selectively inhibit the mitogenic stimulation of cells by
TPA (12-O-tetradecanoyl phorbol 0-acetate [phorbol 12-
myristate ß acetate]) and serum but not by EGF (Wright et
1. Abbreviations used in thispaper: CAT, chloramphenicol acyltransferase;
FB andJB, Fos and Jun/AP-1 DNA-binding domain peptides; GAG, glycos-
aminoglycans; HBP-1, heparin binding peptide; PPS, pentosan polysulfate;
SMC, smooth muscle cells; TK, thymidine kinase; TRE, TPA responsive
element.
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rin-induced trans-repression was observed in primary
vascular smooth muscle cells, as well as in the trans-
formed HeLa cell line and in nondifferentiated F9
teratocarcinoma cells. Inhibition of AP-1-mediated
trans-activation occurred with heparin and pentosan
polysulfate but not with chondroitin sulfate A or C.
Heparin-binding peptides or heparitinase I addition to
nuclear lysates of heparin-treated cells allowed en-
hanced recovery of endogenous AP-1-specific DNA
binding activity. We propose a model in which nuclear
glycosaminoglycans play a trans-regulatory role in al-
tering the patterns of inducible gene expression.
al., 1989 ; Reilly et al., 1989; Pukac et al., 1990). The an-
tiproliferative response was not associated with a decrease
in the level of inducible protein kinase C (PKC) activity
(Wright et al., 1989; Pukac et al., 1990) suggesting that the
intracellular GAG blocked events distal to PKC. Wright et
al. (1989) and Pukac et al. (1990) found that the effects of
heparin on cell proliferation, induced by TPA or serum,
correlates with attenuated levels of cfos and c-myc mRNA.
The expression of these immediate early, or competence
class genes, including cjun, is known to be stimulated by
various mitogens and growth factors (Cochran et al., 1983;
Kelly et al., 1983 ; Greenberg and Ziff, 1984; Kruijer et al .,
1984; Mdller et al., 1984; Greenberg et al., 1985 ; Verma,
1986; Gilman et al ., 1986; Almendral et al., 1988; Chiu et
al., 1988; Lamph et al., 1988; Curran and Franza, 1988;
Verma and Sassone-Corsi, 1989; Vogt and Bos, 1989), and
to precede the onset of protein synthesis required for entry
into S phase or the development ofa more differentiated cel-
lularphenotype. However, under certain conditions their ex-
pression or overexpression results in neoplastic transforma-
tion (Miller et al., 1984; Schiltte et al., 1989).
The proto-oncogene products, Fos and Jun/AP-l, associate
to form a heterodimeric trans-activator complex which binds
with high affinity and specificity to AP-1-like promoter ele-
ments (Angel et al., 1987; Bohmann et al., 1987; Lamph et
al., 1988 ; Rauscher et al., 1988; Sassone-Corsi et al., 1988;
Chiu et al., 1988). The AN site, also described as the TPA-
responsive element (TRE), is characterized by the palin-
31dromic consensus base sequence TGAG/CTCA. Expression
of genes containing the THE is regulated by the interaction
ofthe Fos-Jun/AP-1 trans-activating complex with this DNA
element. TREs have been identified in the 5'-regulatory do-
mains of both the cfos and cjun genomes and both have
been implicated in their autoregulatory function (Gilman et
al., 1986; Sassone-Corsi et al., 1988 ; Kouzarides and Ziff,
1988; Nakabeppu et al., 1988; Angel et al., 1988b; Lu-
cibello et al., 1989; Schuermannet al ., 1989). The promoter
region of cfos is responsive to a variety of mitogens and
growth factors (Treisman, 1985; reviewed in Verma, 1986).
Cell stimulation is followed by a rapid elevation in cfos and
cjun gene expression which, at least in the case of cjun, is
mediated through interaction of the activated Fos-Jun/AP-1
complex with a THE in the 5' region of the genome. When
translated, these oncoproteins bind to and activate other
genescontaining the THE in a coupled amplification process
required to induce cellular proliferative or developmental
events (Müller et al., 1984; Treisman, 1985 ; Lau and Na-
thans, 1987) .
Upon stimulation, a functional dimer of Fos with Jun/AP-1
occurs requiring the leucine-zipper domain of each protein
(Landschultz et al., 1989; Schuermann et al., 1989; Turner
and Tjian, 1989; Busch and Sassone-Corsi, 1990a) . Binding
of the Fos-Jun dimer to the THE is directed by the adjacent
basic DNA-binding domain (Gentz et al., 1989; Nakabeppu
and Nathans, 1989; Busch and Sassone-Corsi, 1990b). We
noted that these DNA-binding domains contained sequences
similar to those previously reported to exhibit high affinity
heparin binding (Cardin and Weintraub, 1989; Jackson et
al., 1991) . The fact that these transcription factors are
heparin-binding proteins and that nuclear heparins have been
previously identified, prompted us to examine the role and
specificity of heparin in the attenuation of nuclear responses
to mitogen . In these studies we have measured the level of
inducible Fos-Jun/AP-1 nuclear activity and demonstrate a
direct nuclear inhibitory role for glycosaminoglycans on
TRE-regulated gene expression.
Materials andMethods
CellCulture
HeLa cells and mouse F9 testicular teratocarcinoma cells were routinely
cultured in DME supplemented with 2mMglutamine, 100 U/ml penicillin,
and 100 mg/ml streptomycin and 10% FCS in an atmosphere of 5% CO2
for HeLa cells and 7% CO2 for F9 cells. Cells were grown in flasks (model
T75; FaLcon Labware, Oxnard, CA) andpassaged 1:3 every 2-4 d with0.1%
trypsintreatmentto release cells fromthe culture plates. Cells fortransfec-
tionexperiments were seeded similarly in 100-mmplates (Falcon Labware);
cells from one T75 flask were divided into 20 100-mm plates. Cells were
split in the above medium and allowed to attach overnight after which the
medium was changed to that supplemented with low serum (0.1% FCS) be-
fore each experiment.
Vascular smooth muscle cells (SMC) were isolated enzymatically from
two to three thoracic aortas ofmale Sprague-Dawley rats (150 g) according
to a modified methodof Ives et al. (1978). Briefly, aseptically obtained aor-
tic strips were predigested at 37°C in serum-free DME containing col-
lagenase (1 mg/ml) and elastase (0.5 mg/ml) for 30 min. The luminal side
of the aorta was gently scraped to remove the endothelium and the medial
layer was separated from the adventitia. The medial layer was rinsed and
digested for an additional 2 h with a fresh enzyme mixture at 37°C. Cells
were grown in DME supplemented with 10% heat-inactivated FCS, 2 mM
L-glutamine, 100 U/ml penicillin G, 100 Wg/ml streptomycin, and 25 mM
Hepes at 37°C with 5% Ct?2 in humidified air. Subculture was performed
every 7 d after the culture had reached confluence. Cultures between the
fifth and ninth passages were used in the present study.
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Cell Transfections and ChloramphenicolAcyl
7ransferase (CAT)
Transient transfections were performed on HeLa, F9 cells, and SMC in cul-
tures seededatround 30% confluence in 100-mmPetri dishes in MEM con-
taining 2 mM glutamine, 10% FCS and 100 U/nil penicillin, and 100 pg/ml
streptomycin as indicated and allowed to attach overnight. Cells were re-fed
with the same medium containing0.1% FCS for theindicated period oftime
with or without 200 pg/ml heparin (porcine gut mucosal, No. 820-5077
MG; Gibco Laboratories, Grand Island, NY) as described in the figure
legends. Cells were washedand re-fedwith the same medium in the absence
of heparin and transfected with the indicated plasmid(s) for 12 h using the
calcium phosphate coprecipitation method as described elsewhere (Gor-
man, 1985). Cultures were then washed and re-fed with the same medium
before TPA treatment as indicated. Afterphorbol ester treatment, cells were
harvested by mechanical scraping and CAT assays were performed with
[14C] chloramphenicol as substrate at 37°C for 2 h as described (Gorman,
1985). 50 Ag ofcell protein per assay was used as determined with the pro-
tein assay kit (BioRad Laboratories, Cambridge, MA) with gamma globu-
lins as protein standards. CAT assays were terminated by extracting each
reaction mixture with 500 Al of ethyl acetate. Extracts were evaporated to
dryness, resolubilized in 30 Al of ethyl acetate and resolved on silica gel
thin layer chromatography plates with a developing solution of chloro-
form/methanol (95:5, vol/vol). Quantitation was achieved by cuttingoutthe
corresponding mono- and diacylated chloramphenicol spots and measuring
the radioactivity. CATspecific activities were determined based on a
[1aC]chloramphenicol specific activity of 60 mCi/mmol.
DNA BindingAssay
HeLa cell nuclear lysates were prepared exactly as described by Dignam
et al. (1983) from a pool of four similarly treated cultures of HeLa cells
(at -50% confluence in 100-mm petri dishes) grown in 0.1% FCS sup-
plemented medium for 48 h. Tb assay lysates for THE binding activity, first
they were dialyzed at4°C against Dignam's buffer D (Dignamet al., 1983).
The assay consisted of 10 Ag protein of each lysate, 1 ng (0.2 pmol) of 32p-
labeledsynthetic metallothioneine IIA THE which contained the consensus
AP-1 binding site (GTGAGTCAG; Lamph et al., 1988), and 2 hg of poly
[dI.dC] unless stated otherwise, to reduce nonspecific binding activity. As-
says were performed in 20 Al of TM buffer (50 mM Tris-HCI, pH 7.9, 12.6
mM MgC12, 1 mM EDTA, 1 mM DTT 20% glycerol). Each tube was
gently vortexed, incubated at room temperature for 20 min, and resolved
on 4% polyacrylamide native gels prepared and electrophoresed in 0.25%
TBE (lx TBE: 50 mM Tris-Borate, pH 8.3, 1 mM EDTA) at 150 V for
1 h as described (Busch and Sassone-Corsi, 19906). Gels were dried and
radioautographed by exposing to film for 4-12 h.
HeparinBindingAssays
Solid-phase assays of 1251-labeled heparin binding to the Fos and Jun/AP-1
DNA-binding domain peptides were performed in Immulon 4 Remowawell
microtiter plates (Dynatech Laboratories, Inc., Alexandria, VA). 125j
labeled heparin was prepared as described by Cardin et al. (1987). Typi-
cally, 1-10 ug of each peptide in 50 A1 were absorbed to the wells for 3 h
at room temperature. Residual peptide was removed by aspiration, and the
wells were washedfive times with250 A1 PBS. In saturation binding experi-
ments, excess amounts of 1251-labeled heparin in 50 AI PBS were added to
each well and allowed to incubate 8 h at room temperature. In each assay,
the radioiodinated ligand was removed by aspiration and thewells were ex-
tensively washed with successive 250-Al aliquots of PBS until residual
counts in thewash were near background. The amount ofbound ligand was
determined by gamma counting. In the absence of peptide, no concentra-
tion-dependent 1251-heparin was bound (<3,000 cpm) to the well surfaces
(data not shown).
Results
Negative Trans-regulation ofJun/ARI-mediated
Transcription byHeparin
Transient transfection studies have been used to study induc-
iblepromoter function for a widevariety of transcription fac-
tors. As a starting point to investigate the role of nuclear
GAGS on phorbol ester-inducible cellular functions, we ex-
32Figure 1. (A) Transient transfection assays were per-
formed usingaTHE/TK-CAT reporter gene construct
in which the metallothionein IIA THE (7GAGTVA)
precedes the herpes thymidine kinase heterologous
promoter (bases -109-+57) and the bacterial CAT
DNA sequence contained in the plasmid (pTEN) as
describedbyVisvader et al . (1988) . (B) Cotransfection
experiments were performed with the THE/TK-CAT
reporter gene construct and the expression vector for
Jun/AP-1, pSV-cjun, which contains theSV-40 early
gene promoter and polyadenylation sequence flanking
the cjun DNA sequence as previously described
(Lamph et al ., 1988) . (C) Heparin pretreatment of
cells reduced trans-activation through theTRE . HeLa
cells were seeded at -30% confluence and re-fed
after attacliment in medium containing 0.2% FCS
with (lanes 1, 5, and6) or without (lanes 2-4) heparin
(200 jig/ml) for 24 h before transfection with the re-
porter plasmidTHE/TK-CAT alone (lanes 1-3, and5)
orcotransfected with pSV-cjun (lanes4and 6) . Con-
trol cells in the absence (lane 7) or presence (lane 8)
ofheparinwere transfected withRSVCAT(Angel etal ., 198ßb) . Equimolaramounts of reporterplasmid andpSV-cjun expression plasmid
or the control plasmid, pTEN (lanes 1-3, 5, 7, and 8), were transfected at a total of 20 jig ofDNAper 10-cm culture dish. After a 12-h
transfection period, cells were washed twice with medium and re-fed under the same conditions with (lanes 1, 5, and 6) or without (lanes
2-4) heparin at 200 14g/ml .TPA (75 ng/ml) was then added for 1 h, and 5 h later cells were harvested (lanes 2 and5) . CAT assays were
performed for 2 h at 37°C using 50 hg of cell protein per assay as described (Gorman, 1985) . (D) Heparin suppression of pSV-cjun-in-
duced THE/TICCATtransactivation is a time-dependent process . HeLa cells were pretreated with heparin for 18, 24, 30, and 36 h before
cotransfection with the THE/TK-CAT reporter plasmid andpSV-cjun expression plasmid . Control lanes 1, 3, 5, and 7were notexposed
to heparin. After heparin treatment for 18 h (lane 2), 24 h (lane 4), 30h(lane 6), or 36 h (lane 8) cells were washed twice with medium
without heparin, re-fed in the absence of heparin and transfected with equal molar concentrations of THE/TK-CAT andpSV-cjun as de-
scribed in C. Parallel control plates without earlier exposure to heparin were transfected at 18 h (lane 1), 24 h (lane 3), 30 h (lane 5),
and 36 h (lane 7) . After a 12-h transfection period, cells were washed twice with medium and re-fed in the absence of heparin . After
a total of 24-h post-heparin incubation, cells were harvested and frozen in liquid nitrogen and kept stored at -70°C until the final time
point was harvested . CAT assays were run simultaneously as described in Methods and Materials .
amined the effects of heparin on THE promoter binding and
transactivation by the Fos-Jun/AP-1 transcription factor
complex . Plasmids containing the bacterial reporter gene
construct THE thymidine kinase (TK)-CAT (Fig . 1 A) were
introduced into cells . The THE promoter element confers
phorbol ester inducibility to the heterologous TK pro-
moter-CAT gene construct (Angel et al ., 1987) . Experi-
mentswere also performedwith this system in which consti-
tutive high level expression of the Jun/AP-1 oncoprotein
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occurred as a result of cotransfecting withacjun expression
vector, pSV-cjun (Fig . 1 B) as described (Lamph et al .,
1988) .
In the first series of experiments, we determined whether
heparin effected THE/TK-CAT expression in HeLa cells af-
terTPA treatment or pSV-cjun cotransfection . The reporter
gene constructRSVCAT (Gorman et al ., 1982) was used as
apositive control to monitorheparin selectivity on promoter
activity. HeLa cells were exposed to low serum levels for
3324 h either in the presence (Fig. 1 C, lanes 1, 5, 6, and 8)
or absence (Fig. 1 C, lanes 2-4, and 7) of heparin as de-
scribed in Materials and Methods. Cells were transfected
with either TRE/TK-CAT (Fig. 1 C, lanes 1-3, and 5), RSV
CAT (Fig. 1 C, lanes 7 and 8) reporter genes alone, or with
both TRE/TK-CAT and pSV-cjun (Fig. 1 C, lanes 4 and 6) .
TPA was added as indicated (Fig. 1 C, lanes 2 and 5) for
1 and 5 h later cells were harvested and assayed for CAT ex-
pression . The results show that heparin did not activate CAT
expression in cells transfected with TRE/TK-CAT alone
(Fig. 1 C, lane 1) indicating that GAGS do not induce an im-
mediate-early gene response in these cells. In the absence
of heparin, activation of TRE/TK-CAT expression occurred
in cells treated with TPA (Fig. 1 C, compare lane 2 with 3)
and in those cotransfected with the expression vector pSV-
cjun which produces high levels of Jun (Fig. 1 C, compare
lane 3 with 4). In contrast, cells pretreated for 24 h with
heparin and then stimulated with TPA (Fig. 1 C, compare
lane 2 with 5) or cotransfection with pSV-cjun (Fig. 1 C,
compare lane 4 with 6) showed no induction of TRE/TK-
CAT expression. Similar attenuation was not observed in
cells transfected with the RSVCAT reporter gene (Fig. 1 C,
lanes land 8). These results demonstrate that heparin shows
some selectivity towards Jun/AP-1-mediated trans-activation
through the TRE. Sinceheparin did not inhibit CAT expres-
sion in cells transfected with the RSV-CAT reporter gene,
this rules out the possibility that the transfection efficiencies
of TRE/TK-CAT were altered as a result of heparin pre-
treatment.
TFme-dependent Vans-Repression by Heparin
In the next experiment, HeLa cells were pretreated with
GAGS for increasing periods of time before transfection to
determine the rate of heparin uptake and transcriptional
repression of Jun/AP-1-induced TRE/TK-CAT expression.
As is demonstrated in Fig. 1 D, up to 18 h of heparin treat-
ment (Fig. 1 D, lane 2) did not significantly effect pSV-c-
jun-induced CAT expression relative to untreated control
cells (Fig. 1 D, lane 1). However, attenuated CAT expression
was observed by 24 and 30 h ofheparin exposure (Fig. 1 D,
compare lane 3 with 4, and lane 5 with 6, respectively). At
36 h (lane 7 and 8), the expression in both control and
heparin-treated cells had dropped significantly, presumably
due to poor transfection efficiencies, as cellscontinued to di-
vide and approached confluence. Thus, the inhibition of
TRE/TK-CAT expression in HeLa cells by heparin required
their continuousexposure to GAGS for -18-24 h. Moreover
this trans-regulatory response did not result in growth arrest
in the HeLa transformed cell line. The time required to ob-
serve the onset of trans-repression is consistent with that
observed previously for the heparin-induced changes in the
collagen phenotype expressed in unsynchronized vascular
SMCs (Majack and Bornstein, 1985)and the level of hepatic
triglyceride lipase expression in HepG2 cells (Busch et al .,
1989) .
HeparinMediates Antiproliferative
and Trans-Repressional Responses
inRat VascularSMCs
Heparin treatmentof HeLa cellsis not associated with an an-
tiproliferative effect (Fig. 1 D and Busch, S. J., unpublished
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Figure 2. (A) Heparin trans-
repression of TRE/TK-CAT
-~ 300
￿
expression in vascular SMC.
Rat vascular SMC were cul-
tured as described in Materi-
als and Methods. Transfection
withthe TRE/TKCATreporter
gene was performed on cells
with no prior heparin expo-
sure (lanes 1, 3, and 6) orafter
2
￿
3
￿
4
￿
5
￿
6
￿
a 24-h pretreatment with 200
pg/mlheparin (lanes 2, 4, and
5). After an 18-h transfection, cells were washed and 15 minbefore
induction with TPA, some cultures received 200 pg/ml heparin for
the first time (lane 6) or as a secondary exposure (lane 5), which
was then present throughout the induction phase. TPA treatment
and CAT expression proceeded for 6 h, and cells were then har-
vested and assayed for CAT activity. Thin layer chromatography
resolved assays were quantitated and expressed as CATspecific ac-
tivity. Data represents the mean f standard deviation of three
experiments.
34
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results) in contrast to that reported previously for primary
SMC cultures (Pukac et al., 1990). As HeLa cells are a
transformed cell type, we examined whether GAG-mediated
trans-repression of AN activity would accompany an anti-
proliferative response in primary rat vascular SMCs. In this
experiment the TRE/TK-CAT reporter gene was transiently
transfected into SMC with or without a 24-h heparin pre-
treatment . After transfection some cultures received their
only heparin treatment (Fig. 2, lane 6) or a secondary treat-
ment (Fig. 2, lane 5), 15 min before TPA induction . Whereas
heparin pretreatment did not alter basal levels of TRE/TK-
CAT expression (Fig. 2, lane 2), it completely abolished the
TPA inducibility (Fig. 2, compare lane 3 with 4) . In contrast
to HeLa cells, which requires an 18-24-h exposure to hepa-
rin for trans-repression, a 15-min exposure before phorbol
ester treatment was sufficient to abolish TRE/TK-CAT in-
duction by TPA in SMC (Fig. 2, lanes 5 and 6). The antipro-
liferative effects of 200 pg/ml heparin was determined in
parallel experiments by measuring [3H]thymidine incorpo-
ration. Consistent with previous reports, SMC required 50
min-2 h for half-maximal inhibition of this proliferative re-
sponse with an associated ECso of 50 pg/ml.
Heparin Inhibits thePhorbolEsterStimulation
ofARI in NondiferentiatedF9 Cells
We next examined the ability of heparin to effect TRE-
inducible promoter function in murine F9 testicular ter-
atocarcinoma stem cells, a nondifferentiated stem cell line.
This cell line has low basal AN activities(Chin et al., 1988)
that allow transfection to precede heparin treatment without
generating excessive background levels of CAT expression.
As shown in Fig. 3, there is little or no Fos-Jun/AP-1 intrin-
sic activity present in uninduced F9 cells in either the ab-
senceor presence of heparin (Fig. 3, lanes 1 and 2, respec-
tively) . In contrast, cotransfection with pSV-cjun plus
TRE/TK-CAT resulted in strong induction of CAT expres-
sion in the presence ofTPA (Fig. 3, lane 3) and was repressed
by >90 % in cells treated with heparin for 24 h before phor-
bol ester stimulation, (Fig. 3, lane 4). TPA treatment accom-Figure3 . cjun/AP-1 transactivation ofTRE/TK-CAT expression is
blocked in nondifferentiated F9 cells by posttransfection heparin
treatment . F9 embryonaltetracarcinoma stem cells were grownand
transfected as described in Materials and Methods with TRE/TK-
CAT and control plasmid pTEN (lanes 1 and 2), or cotransfected
with an equimolar concentration ofTRE/TK-CAT and pSV-cjun
(lanes 3and 4) . Aftera12-h transfection period, cells were washed
twice with medium and re-fed with the same plus (lanes 2 and 4)
or minus (lanes 1 and 3) 200 ug/ml of heparin. After 24 h cells
were exposed to TPA (75 ng/ml) for 1 h, and 5 h later cells were
harvested and assayed for CAT activity.
panyingpSV-cjun cotransfection optimizedCATexpression
in this cell line (Busch, S . J., unpublished results) . These
data show that heparin strongly attenuates phorbol ester-in-
ducible gene expression mediated through aTHE promoter
in distinct cell types ; in SMC having a nontransformed and
differentiated phenotype, in HeLa cells that exhibit a trans-
formed and partially differentiated phenotype, and in F9 stem
cells with a transformed and nondifferentiated phenotype .
Selective Rans-Repression by Heparin
and Pentosan Polysulfate
We have demonstrated the promoter selectivity of GAG-
mediated transcriptional repression in Fig. 1 by showing a
lack of trans-repression of theRSV promoter CAT reporter
gene construct in HeLa cells . To further examine the spec-
ificity of GAG-attenuated promoter function, we compared
heparinwith several otherGAGs for their ability to produce
an altered transcriptional response in HeLa cells . In Fig. 4,
THE/TKCAT expression wasdetermined in both uninduced
andTPAinduced HeLa cellswithout earlier GAG treatment
(NONE), or after a 24-h pretreatment with either heparin,
chondroitin sulfate A, pentosan polysulfate, or chondroitin
sulfate C. As shown, TPA induced a similar level of CAT
expression in the control, chondroitin sulfate A-, and chon-
droitin sulfate C-treated cells. In contrast, heparin and pen-
tosan polysulfate-treated cells had both a diminished back-
ground (open bars) and TPA-induced leveloftranscriptional
activity (hatched bars). There was no significant difference
in total cell numbers in cultures grown in the absence or
presence of heparin or pentosan polysulfate (PPS), which
again suggests that suppressed Fos-Jun/AP-1 transcriptional
activity does not correlate with growth arrest in HeLa cells .
These data further suggest that trans-repression of the Fos-
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Figure 4 . Specificity of GAGs on TPAinducible THE/TK-CAT.
HeLa cells seeded at 20% confluence were re-fed in normal
medium containing0.2% FCS and either noGAG (NONE), or 200
p.g/ml of heparin (H), chondroitin sulfate-A (CsA ; No . c8529,
SigmaChemical Co ., St . Louis, MO), pentosan polysulfate (PPS ;
No . p8275, Sigma ChemicalCo.), or chondroitin sulfate-C (Cs-C,
No . c4384, Sigma Chemical Co .) . After incubating 24 h in the
presenceofthe indicatedGAG, cells were washedtwice and theme-
dium was replaced with normal medium containing 0.1% FCS and
no GAG . Cells were then transfected for 12 h with 10 jig ofTRE/
TK-CAT, washed, and re-fed with medium containing 0.1% FCS
and stimulated with TPA (75 ng/ml, u) or with the carrier solvent
(7,ul ethanol, c) for6h. Cells were then harvestedandassayed for
CAT activity as described in MaterialsandMethods . (A)Aqualita-
tive evaluation by radioautographs from a typical experiment . Un-
induced levels ofCAT expressions (lanes 1, 3, S, 7, and 9) arecom-
pared with TPA-induced levels after no pretreatment (lane 2),
heparin pretreatment (lane 4), chondroitin sulfateA pretreatment
(lane 6), pentosan polysulfate (lane 8), or chondroitin sulfateC
(lane 10). (B) CATspecific activity was quantitated and is shown
as the mean of three experiments as described in Materials and
Methods .
Jun/AP-1 transcription factor complex is not ageneralprop-
erty of sulfated polysaccharides but is selective for heparin
and its homopolysaccharide analogue, PPS.
Heparin Competesfor Promoter Binding
by Interacting with the BasicDNA-bindingDomain
ofFos-JunlAPLI
Glycosaminoglycans have been shown to enter the cell
35Figure 5 . (A) Heparin reversibly blocks Fos-Jun/AP-1 binding to
in vitro . HeLa cell nuclear lysates were prepared from
-induced cellsby themethod of Dignarn et al . (1983) and as-
WKTHEbinding activity ofintrinsic Fos-Jun, in thepresence
absence of heparin added in vitro. In lanes 6-10, a heparin-
ding peptide(HBP 1, amino acid sequence KSKTSKRKIR) was included to demonstratereversibility ofbinding inhibition. Binding
assays contained 10 Ag (protein) aliquots of the induced lysate,
2 tag ofpolyPAC], and I ng of 32P-TRE without heparin (lanes I
and 6) or with the indicated amount of heparin
without {lanes 1-5) or with {lanes 6-10) HBP-I. (B) Fos and Jun/AP-1 DNAbinding
domain peptides bind heparin. A vitro heparin binding to synthetic polypeptides representing the Fos (residues 139-161) and Jun/API
(residues 257-279) DNAbindingdomains (synthesized as"My reported in Busch and Sassone-Corsi, 1990b), was measured with
1251-heparin prepared exactly as described by Cardin etAQ98' ."s were adsorbed to 96-wellImmulon4 RemavawellTm plates at
increasing concentrations 0WO leg}Q3 ha room temperature . Wells were then washed 5 times with 250 jal PBS (10mM sodium
phosphate, pH 74, 150WNCO to remove trace unbound peptide . An excess of 1251-heparin was ten added to each coated well and
incubated 8 h at room temperature as described in Materials andMethods. After removal of unbound 10-heparin, and
bound 14"nwas"ated by gamma counting.QNs") and Jun/AP-1 (JB) DNA . binding domain peptides compete
hibitory heparin inv" DNAbinding assays were performedwith"induced"cell nuclear lysates and a 32Plabeled THE
absence (lane 1) or presence (lanes 2-7) of200 ng heparin without FB or JB peptide addition (lanes 2 and5) or after adding FB (lanes
and 4) or JB (lanes band 7) . Nuclear lysates JO tag) were added to 10 jAl of2x TM (see Materials and Methods) containing the indicated
concentrations of heparinandpeptide (poly [dI.dC] was excluded)Wpreincubated togetherQ 10 min"addition of 32P-TRE . Mix-
tures were then incubated at room temperature for20 min before gel resolution.through high affinity receptor-mediated processes (Castellot
etal., 1985b; Resink et al ., 1989), and in the case ofprimary
hepatocytes, specific GAG subfractions have been shown to
concentrate in the nucleus (Fedarko and Conrad, 1986; Ishi-
hara et al., 1986, 1987) . To determine whether the attenu-
ated promoter function observed in the previous experiments
was because of the presence of an inhibitory nuclear GAG,
the relative level of TPA-inducible TRE-binding activity in
HeLa cell nuclear lysates was examined by polyacrylamide
gel DNAbinding assays. We first examined heparids ability
to compete for promoter binding activity upon direct addi-
tion of the GAG to the assays. In Fig. 5 A (lanes 2-5), addi-
tion of heparin to nuclear lysates from TPA-induced cells
blocked the intrinsic Fos-Jun/AP-1 binding activity (arrow)
to the TRE in a dose-dependent manner. The induced bind-
ing activity was shown to be because of specific interactions
by Fos-Jun/AP-1 with the TRE based on the ability of unla-
beled THE to specifically compete for binding and antifos
and antijun antibodies to block THE complex formation
(Busch and Sassone-Corsi, 1990b). The observed inhibition
by heparin was completely reversed in the presence ofHBP-1,
a heparin-binding peptide (Fig. 5 A, lanes 6-10) (Martin
et al., 1988). These findings show that the presence of hepa-
rin in the nuclear lysate completely inhibits the promoter
binding activity ofendogenous Fos/Jun and that a competing
heparin-binding peptide protects against inhibition by GAG.
In reviewing the activity with HBP-1, attention was then fo-
cused on the heparin-binding properties ofthe Fos/Jun DNA
binding regions. Peptide regions of Fos (FB-1, residues
139-161) and the Jun (JB, residues 257-279) representing the
DNA-binding domains were synthesized. These peptides
were selected as the most likely domains to bind heparin
based on a comparison of their amino acid sequences to
those of known heparin-binding proteins (Cardin et al.,
1987; Jackson et al., 1991) . Furthermore, if heparin bound
to these domains in the intact Fos and Jun proteins it would
be expected to blockDNA binding competitively. To test this
hypothesis, first we examined the ability of I'll-labeled
heparin to bind directly to FB-1 and JB (Fig. 5 B) . As is
shown, the Fos (FB1) and Jun (JB) peptides bound heparin
and exhibited similar heparin-binding capacities. We then
tested these peptides in DNA-binding assays for their ability
to reverse heparin competition for THE binding (Fig. 5 C).
A TPA-induced nuclear lysate prepared from HeLa cells ex-
hibited high levels of endogenous Fos-Jun/AP-1 binding ac-
tivity (Fig. 5 C, lane 1, arrow) which was completely in-
hibited by the addition of heparin (10 ng/pl) (Fig. 5 C, lanes
2 and 5). FB-1 and JB DNA-binding domain peptides, like
HBF-1, when titrated into each binding assay (Fig. 5 C, lanes
3 and 4, and 6 and 7, respectively) reversed the inhibition by
heparin. These results demonstrate that inhibition of Fos-
Jun/AP-1 binding to the TRE by heparin in vitro is reversible
by the heparin-binding Fos and Jun/AP-1 DNA-binding do-
main peptides.
Heparin Inhibits TPA Induction ofNuclear ARI
BindingActivity
To determine if heparin has an effect on the TPA-inducible
levels of TRE binding activity in intact cells, HeLa cell nu-
clear lysates wereprepared and the endogenous TRE binding
levels in these lysates were determined from control (un-
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treated and uninduced) cells(Fig. 6 A, lane 1), untreated and
TPA-induced cells (Fig. 6 A, lane 2), and heparin-treated and
TPA-induced cells (Fig. 6 A, lane 3) . As demonstrated, the
intrinsic levels of Fos-Jun/AP-l binding activity was strongly
activated in untreated TPA-induced cells (Fig. 6 A, lane 2) .
However, after heparin pretreatment, TPA was unable to in-
duce an equivalent level of THE binding activity (Fig. 6 A,
lane 3). The addition of an equivalent concentration of hepa-
rin to all cell cultures just before harvest (see legend to Fig.
6 A) eliminates the possibility that the nuclear GAG arrive
artifactually during lysate preparation. These data suggest
that blocked transactivation of TRE/TK-CAT (see Figs. 2-5)
correlates with reduced levels of TRE-promoter binding ac-
tivity in response to TPA treatment in cells preconditioned
with heparin.
In Fig. 6 A, heparin treatment inhibited Fos-Jun/AP-1
binding activation in pretreated cells by either a direct or in-
direct mechanism. To determine if the inhibitory activity
was active in nuclear lysates of heparin pretreated cells, the
nuclear lysate from lane 3 (see Fig. 6 A) was added to that
from TPA-induced cells (Fig. 6 A, lane 2) and binding activ-
ity was measured. As is shown in lane 4, addition of the in-
hibited nuclear lysate to the TPA-induced lysate abolished
the strong THE binding activity originally observed (Fig. 6
A, lane 2). These data demonstrate that the inhibitor ofTRE
binding is present in excess and is active in the nuclear ly-
sates of heparin-treated cells. Addition of nuclear lysates
from untreated control cellsdid not inhibit the THE binding
activity in nuclear lysates of TPA-induced cells (data not
shown). To establish whether or not Fos-Jun/AP-1 binding
activity was present but was inhibited by a nuclear heparin
in lysates of GAG-pretreated cells, the GAG-inhibited nu-
clear lysate (Fig. 6 A, lane 3) was preincubated with the FB-1
and JB peptides before assay and THE binding activity deter-
mined . As shown in Fig. 6 B, both FB-1 (lanes 2-6) and JB
(lanes 8-11) allowed a partial recovery ofTRE binding activ-
ity when compared to nuclear lysates of TPA-treated cells
alone (compare to lane 1). These findings support the con-
clusion that GAGs or some other factor(s) present in the nu-
clear lysates of heparin-conditioned cells recognizes and
binds to the DNA-binding domain of Fos and Jun/AP-1 and
is responsible for the attenuation of phorbol ester-inducible
Fos-Jun/AP-1 binding and trans-activation activity through
a THE promoter element.
Direct EvidenceforHeparin in the Nucleus
Both the nuclear lysate mixing experiments described above
and the nuclear reconstitution experiments in which heparin
and peptides were exogenously added are consistent with
heparids ability to effect nuclear transcription factor func-
tion. However, it is also possible that heparin-treatment
stimulates the cells to synthesize or stimulate an inhibitory
protein that could effect nuclear AP-I function by interacting
with the DNA binding domains of Fos and Jun/AP-1. To pro-
vide direct evidence for the presence of nuclear GAG, nu-
clear lysates prepared from HeLa cells were digested with
highly purified heparitinase and then endogenous THE bind-
ing activity was determined. This enzyme digests glycosami-
noglycans enriched in heparan sulfate to release uronic acid.
In Fig. 6 C, nuclear lysates were prepared from HeLa cells
and analyzed for TRE binding activity as described, without
(Fig. 6 C, lanes 1, 3, 5, and 7) or with (lanes 2, 4, 6, and
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388) a predigestion with heparitinase. Heparitinase digestion
on untreated control nuclear lysates caused a twofold enrich-
ment in binding activity. This enrichment was observed in
control cells whether or not heparin was added to the me-
dium before cell harvest suggesting that GAGs are intrinsic
to the nucleus and compete with DNA for binding to tran-
scription factors. Heparitinase digestion of heparin-treated
control cells showed a similar increase in binding activity as
observed in untreated controls (Fig. 6 C, lanes 7 and 8) .
Heparin pretreatment again prevented phorbol ester induc-
tion of THE binding activity (Fig. 6 C, compare lane 3 with
5) with a much greater increase in binding activity after
heparitinase digestion than seen in controls (Fig. 6 C, com-
pare lane 2 with 6). Heparitinase enhancement was also ob-
served in uninduced heparin-treated cells (Fig. 6 C, lanes 7
and 8). In lanes 9-11, heparitinase digestion of inhibitory
GAG is demonstrated in which a synthetic polypeptide corre-
sponding to the yeast AP-1 binding protein GCN4 (residues
221-281 that compose the core sequence sufficient for pro-
tein dimerization and DNA binding) forms a complex with
the THE (Fig. 6 C, lane 9) which was blocked upon addition
of heparin (Fig. 6 C, lane 11). When heparitinase was added
to GAG-inhibited GCN4, binding activity was restored (Fig.
6 C, lane 10) . These data suggest that inhibition oftranscrip-
tional activation of cellular Fos and Jun is a direct result of
nuclear heparin sulfate (which are targeted by heparitinase)
content and that untreated control cells also exhibit nuclear
GAG activity. Heparin treatment must increase the concen-
tration of nuclear GAG to levels sufficient to trans-repress
TPAinducible AP-1-associated gene transcription.
Discussion
Expression of the proto-oncogenes cfos and cjun/AP-1 can
be induced by several agents (Greenberg et al ., 1985; Boh-
mann et al ., 1987; Kouzarides and Ziff, 1988; Nakabeppu
et al., 1988; Schuermann et al ., 1989). The phorbol ester,
TPA, while not sufficient to induce transformation in cell§
can activate the protein kinase C pathway (Nishizuka, 1986);
increase binding of the Fos-Jun/AP-1 transcription factor
complex to a THE (Angel et al ., 19ß8b; Turner and Tjian,
1989); induce the cfos gene through a THE found in its pro-
moter or through the dyade symmetry element (Treisman,
1985; Verma, 1986; Visvader et al., 1988; Verma and
Sassone-Corsi, 1989), which is known to bind the nuclear
factor SRF (Treisman, 1985; Gilman et al., 1986) ; and in-
duce cjun expression (Angel et al., 1987, 19ß8b; Visvader
et al., 1988). Transfection of cellswith the Jun/AP-l expres-
sion vector pSV-cyun mimics the response to TPA, and
results in elevated THE binding activity and expression of
genesthat contain this element in their promoter. In the pres-
ent studies, cotransfection with the pSV-cjun expression
vector and the THE/TK-CAT reporter gene construct was
used to monitor specifically Jun-mediated activity in cells
afterheparin treatment. The results of Fig. 1 show that hepa-
rin treatment of HeLa cells for 18-24 h blocks TPA-induced
and pSV-cjun-induced trans-activation through a THE
without a comparable effect on Rous sarcoma viral LTR pro-
moter. These findings suggest that GAG-mediated trans-
regulation may be promoter selective. Studies are currently
being expanded to compare regulatory responses to a variety
of constitutive and inducible transcription factor-specific
promoter elements.
Our results in SMC (Fig. 2) are consistent with the sugges-
tion by Wrightet al. (1989) that heparin inhibits TPA-induced
SMC proliferation by decreasing coupled proliferation-re-
sponsive gene expression. Pukac et al., (1990) demonstrated
that heparin does not alterprotein kinase C activity to effect
a change in growth rate. These authors suggested that tran-
scriptional rates of the cfos and c-myc induced by TPA may
have been affected. In contrast to HeLa cells, primary vascu-
lar SMC showedtrans-repression ofinducibleAP-1-mediated
gene expression and growth arrest suggesting that heparin-
inhibitable Fos and Jun/AP-1 activity is coupled to re-entry
of arrested cells into G,-phase of the cell cycle. Moreover,
the rapid response to heparin by these cells when compared
to HeLa cells may reflect the large number of high affinity
receptors (103/cell, Kd 10-9 M, Castellot et al., 19ß5b) on
the SMC surface. Heparin also blocked inducible AP-1-medi-
ated gene expression in nondifferentiated F9 cells suggesting
Figure 6. (A) TPAinducible Fos-Jun/AP-1 binding activity is inhibited in heparin-pretreated cell nuclear lysate. HeLa cells were grown
in 10-cmplates to -60% confluence in DME as described in Materials and Methods. Cells were seeded and allowed to attach overnight
in normal medium followed by a 24-h initial treatment period in 0.2% FCS supplemented medium (+ or - heparin, 200 Wg/ml) and a
second treatment period for 1 h (+ or - TPA, 75 ng/ml) . After TPAtreatment, allplates were adjusted to 2001ug/ml with heparin, washed
twice with PBS, and nuclear lysates wereprepared exactly as described by Dignam et al. (1983). Binding assays were conducted as described
in Materials and Methods. Cells were prepared under one of the following threeconditions: 0.2% FCS supplemented medium (control,
lane 1), medium with a 1-h TPA (lane 2) treatment before cell harvest, or medium containing 200,ug/ml heparin for 24 h, followed by
a 1-h TPA treatment (lane 3) before cell harvest. In lane 4, the nuclear lysates from TPAinduced cells (lane2) and the heparin-pretreated
TPA-treated cells (lane 3) were combined before assay. (B) Fos (FB-1) and Jun/AP-1 (JB) DNA-binding domain peptides allow recovery
of Fos-Jun/AP-1 binding activity in nuclear lysates prepared from heparin-treated, TPAinduced HeLa cells. DNA binding assays were
performed on the same lysates as in A ; TPA-induced HeLa cell nuclear lysate (lane 1) or on the inhibited lysates from heparin-pretreated
TPA-treated HeLa cells in the absence (lanes 2 and 7) or presence of FB-1 (lanes 3-6) or JB (lanes 8-11). Nuclear lysates were mixed
with the indicated concentration ofpeptide for 10 min before addition of 32P-TRE in 10 pl of 2x TM (see Materials and Methods) . Mix-
tures were incubated for 20 min (in the absence ofpoly [dl.dC]) and resolved as described in Materials and Methods. (C) Heparitinase
digestion increases recovery of THE binding activity in nuclear extracts. Nuclear extracts were incubated at 37°C in 1X TM containing
1 mM PMSF with or without 10 Uof type I heparitinase (Sigma Chemical Co.) for 1 h before addition of poly MAC and 32F-TRE. Mix-
tures that were incubated without (lanes 1, 3, 5, and 7) or with (lanes 2, 4, 6, and 8) heparitinase were then resolved as described in
Materials and Methods. Lanes 1 and 2, control untreated cells; lanes 3 and 4, TPAtreated cells; lanesS and 6, heparin plus TPAtreated
cells; lanes land 8, heparin-treated cells. Lanes 9-11, the yeast GCN4 core peptide (residues 221-281) with THE binding activity (lane
9) is inhibited by the direct addition of heparin to the binding reaction (lane 11) which is prevented with the simultaneous addition of
heparitinase (lane 10).
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39that the heparin-responsive pathway is a ubiquitous cellular
pathway. This conclusion is consistent with a number of stud-
ies in which nondifferentiated or dedifferentiated cellsin cul-
ture respond to GAG treatments to develop or regain a differ-
entiated phenotype (Jackson et al ., 1991).
The fact that in HeLa cells inhibition of TPA-induced
Fos-Jun/AP-1 activity by heparin was not associated with
cell cycle arrest demonstrates that cjun and cfos activation
(competence gene expression) is not required for continuous
growth in these cells. Castellot et al . (19ß5a) reported earlier
that heparin growth sensitivity is a cell-specific phenomena
in which both proliferation rates and gene expression profiles
are affected. SMC were found to be the most sensitive and
transformed cell types the least. Our results comparing the
rate at which heparin can attenuate the nuclear transcrip-
tional response in SMC and HeLa cells in which 15 min of
heparin treatment was sufficient to abolish a TPA response
in SMC while 18-24 h was required in HeLa cells (compare
Fig. 1 with 2) may be explained by a difference in the number
of heparin receptors on the cell surface although to date, the
number ofheparin-binding siteson HeLa cells has not been
determined. Castellot et al. (19ß5a) and others (reviewed in
Jackson et al ., 1991) have also reported alteration ofcellular
mRNA profiles in response to GAG or matrix-component
treatments. The fact that transcriptional activation through
the AP-1 promoter element is one of the earliest transcrip-
tional events activated in response to growth factors and
mitogens and since heparin can only block induction by cer-
tain stimulatory agents (Wright et al ., 1989; Pukac et al.,
1990) may suggest that nuclear GAGs function to allow for
selective processes to dominate at certain times in devel-
opment.
In the current study, we conclude that nuclear GAGs alter
the level of TPAinducible gene expression by interfering
with the THE binding activity ofthe Fos-Jun/AP-1 transcrip-
tion factor complex. While the binding analysis of nuclear
lysate preparations still suffers from the potential argument
that heparin arrival in the nuclear lysate occurred at the time
of cell lysis, we have controlled for that possibility by in-
troducing heparin to all cellsjust before lysis. The conclu-
sion that nuclear GAG inhibit by direct transcription factor
interaction is based on the presence of inhibitory activity in
heparin-pretreated cell nuclear lysates (Fig. 6) . This activity
was reversible with heparin-binding peptides, including the
Fos and Jun basic DNA-binding domain peptides and by
digestion with the GAG-specific enzyme, heparitinase. The
Fos and Jun DNA-binding domain peptides as well as that
of the homologous yeast transcription factor GCN4 (Saudek
et al., 1991), are knownto possess intrinsic a-helical struc-
ture (Patel et al., 1990; Busch and Sassone-Corsi, 1990a)
and affinity for their promoter element (Busch and Sassone-
Corsi, 1990b). The results of the binding experiments sup-
port the conclusions from the transient transfection studies
and provide evidence for a possible mechanism of action in
which nuclear GAG act as a direct competitive inhibitor of
DNA thereby blocking the trans-activation response. Castel-
lot et al. (1986) reported the inhibition of SMC proliferation
by GAG required the presence of a 3-0-sulfated pentasac-
charide. Similarly, Resink et al. (1989) found that pentosan
polysulfate and heparin were competitive for the same cellu-
lar binding site and that both were inhibitory to vascular
SMC proliferation . That pentosan polysulfate blocked the
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induction ofTHE/TK-CATexpression whilechondroitin sul-
fate A and C did not, shows a specificity for GAG structure
which may be related to the degree and/or pattern of sulfa-
tion. As the 3-0-pattern of sulfation is characteristic of both
heparin and PPS but notchondroitin sulfate A and C, we sug-
gest that this structural feature is required for trans-repres-
sion. This type of structural information may be important
for future studies designed to develop anticancer drugs for
specific nuclear transcription factor targets.
Transcriptional repressors are knownto play an important
role in growth and development (Levine and Manley, 1989;
Ohkuma et al ., 1990). Controlled growth and development
requires precisely regulated levels of gene expression, in
particular for those encoding the oncoproteins (Bishop,
1985). Nuclear GAG interactions with transcription factors
provides the cell with a novel method to both regulate the ac-
tivity of and stabilize nuclear proteins. By attenuating the
transcriptional activation of some inducible transcription
factors, coupled gene reactivation might be similarly attenu-
ated. This may account for the coupled trans-repression ob-
served forboth cfos and c-nlyc described previously (Müller
et al., 1984; Wright et al., 1989) . By stabilizing pools of
transcription factors, GAG protect them from degradation
thereby providing a reservoir ofreadily available activity. Al-
ternatively, at times when the concentration of GAGs reach
competitive levels in the nucleus, transcriptional activity
may be attenuated and certain auto-inducible transcription
factor activity spikes may be blocked. In primary cultures
of nontransformed cells, such regulatory molecules may be
required to prevent cell cycle re-entry, perhaps, to allow cells
to develop or maintain a more specialized phenotype. The
general outcome of such cell matrix- or GAG-mediated
trans-regulatory events is that cells express an altered
phenotype.
The sequence of events involved in such GAG-mediated
regulation of nuclear transcription factors is unclear. The
many steps involved in the regulation and accumulation of
nuclear GAGs include: selective synthesis (Fritze et al.,
1985 ; Bassols and Massqué, 1988; Carey and Evans, 1989)
and secretion of both free (Piepkorn et al ., 1989) and at-
tached chains to cell surface and cell matrix proteoglycans
(Ishihara et al., 1987; Jalkanen et al., 19887; Carey and
Evans, 1989); cellular secretion of heparitinases, pro-
teinases, and phospholipases (Castellot et al., 1982; Jalka-
nen et al., 1987; Ishihara et al., 1987; Nakajima et al., 1987,
1988) required for release and uptake of GAGs; specific
binding and internalization ofGAGs by cell surface receptors
(Hoover et al ., 1980 ; Castellot et al., 19ß5b; Resink et al.,
1989); and transport and metabolism in the cytosol and
translocation into the nucleus (Castellot et al., 19ß5b;
Fedarko and Conrad, 1986; Ishihara et al., 1986; Herbert
and Maffrand, 1989). Regulation at any or all of these steps
may precede regulation of transcription factor activities by
selective nuclear interactions with GAG.
As depicted in Fig. 7, nuclear uptake of GAGs is likely to
be a highly selective and tightly regulated process, otherwise
the nuclear content of GAG would have a heterogeneous
composition depending on what was available in the cellular
matrix. This is apparently not the case for hepatocytes (Ishi-
hara et al., 1986; Fedarko et al., 1986, 1989). It has also
been demonstrated that changes in composition of cell sur-
face-associated GAGs to a more suppressive form occur as
40Figure 7 . A proposed model for nuclear glycosaminoglycan modu-
lation of transcription factor activity. Internalized GAG are trans-
ported to the nucleus by some as yet undefined process where they
bind to specific nuclear proteins . In this model the Fos-Jun/AP-1
transcription factor complex is bound up and as such is rendered
stable and inactive for binding to DNA . The factors or conditions
which reverse this process may include decrease nuclearGAG con-
centrations possibly because of endogenous heparitinase activity,
protein-protein interactions, and phosphorylation events .
a function of cell density in tissue culture (Fritze et al ., 1985 ;
Ishihara et al ., 1987 ; Fedarko et al., 1989) or in vivo
(Thesleff et al ., 1987) . Suppressive effects on cell migration
and proliferation have also been observed in vivo after hepa-
rin infusion (Clowes and Kamovsky, 1977 ; Guyton et al .,
1980 ; Benitz et al ., 1986 ; Thesleff et al., 1987) . The obser-
vation that the "nearest neighbor cell type influences cellu-
lar proliferation and differentiation by production of specific
proteoglycans and glycosaminoglycans (Morrison-Graham
and Weston, 1989) has important implications in the role of
these matrix molecules in embryogenesis and growth per-
haps as they relate to regulating the timing and pattern of
gene expression required for the development of a differen-
tiated phenotype . Our study provides evidence that heparin
and similar sulfated polysaccharides play an antagonistic
role to modulate inducible-transcription factor function . We
propose that such attenuation helps to promote differentia-
tion by stabilizing a specific cell phenotype .
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